Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Signal Transduction in the Blood-Brain Barriers
Reactive astrocytes as therapeutic targets for CNS disorders.
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Imaging Neurodegeneration and Repair in Multiple Sclerosis
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Ofatumumab
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Genetics of multiple sclerosis: swimming in an ocean of data.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Amiloride: a molecular probe of sodium transport in tissues and cells.
Good Early Results for HERV Suppressor in MS
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.

Pages